Last reviewed · How we verify

diclofenac diethylamine, DDEA 2.32% gel — Competitive Intelligence Brief

diclofenac diethylamine, DDEA 2.32% gel (diclofenac diethylamine, DDEA 2.32% gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Rheumatology.

phase 3 NSAID COX-2 Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

diclofenac diethylamine, DDEA 2.32% gel (diclofenac diethylamine, DDEA 2.32% gel) — Novartis. Diclofenac diethylamine works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to a reduction in inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
diclofenac diethylamine, DDEA 2.32% gel TARGET diclofenac diethylamine, DDEA 2.32% gel Novartis phase 3 NSAID COX-2
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) marketed Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Ketorolac Ophthalmic Solution Ketorolac Ophthalmic Solution Bausch & Lomb Incorporated marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2)
hydrochloride hydromorphone + flurbiprofen axetil hydrochloride hydromorphone + flurbiprofen axetil First Affiliated Hospital, Sun Yat-Sen University marketed Opioid analgesic + NSAID combination Mu-opioid receptor (hydromorphone); COX-1/COX-2 (flurbiprofen axetil)
Pranoprofen eye drops Pranoprofen eye drops Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)
ketorolac 0.5% ketorolac 0.5% Queen's University marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). diclofenac diethylamine, DDEA 2.32% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-diethylamine-ddea-2-32-gel. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: